Last reviewed · How we verify

GnRH analogue (Zoladex)

University of Edinburgh · FDA-approved active Small molecule

GnRH analogue (Zoladex) is a GnRH agonist Small molecule drug developed by University of Edinburgh. It is currently FDA-approved for Metastatic prostate cancer, Locally advanced prostate cancer (in combination with radiotherapy), Endometriosis.

Zoladex is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production.

Zoladex is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production. Used for Metastatic prostate cancer, Locally advanced prostate cancer (in combination with radiotherapy), Endometriosis.

At a glance

Generic nameGnRH analogue (Zoladex)
SponsorUniversity of Edinburgh
Drug classGnRH agonist
TargetGnRH receptor
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Zoladex (goserelin) binds to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH followed by sustained suppression of these hormones. This results in castration-level testosterone in males and estrogen suppression in females, making it effective for hormone-sensitive cancers and certain gynecological conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GnRH analogue (Zoladex)

What is GnRH analogue (Zoladex)?

GnRH analogue (Zoladex) is a GnRH agonist drug developed by University of Edinburgh, indicated for Metastatic prostate cancer, Locally advanced prostate cancer (in combination with radiotherapy), Endometriosis.

How does GnRH analogue (Zoladex) work?

Zoladex is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production.

What is GnRH analogue (Zoladex) used for?

GnRH analogue (Zoladex) is indicated for Metastatic prostate cancer, Locally advanced prostate cancer (in combination with radiotherapy), Endometriosis, Uterine fibroids, Breast cancer (premenopausal women).

Who makes GnRH analogue (Zoladex)?

GnRH analogue (Zoladex) is developed and marketed by University of Edinburgh (see full University of Edinburgh pipeline at /company/university-of-edinburgh).

What drug class is GnRH analogue (Zoladex) in?

GnRH analogue (Zoladex) belongs to the GnRH agonist class. See all GnRH agonist drugs at /class/gnrh-agonist.

What development phase is GnRH analogue (Zoladex) in?

GnRH analogue (Zoladex) is FDA-approved (marketed).

What are the side effects of GnRH analogue (Zoladex)?

Common side effects of GnRH analogue (Zoladex) include Hot flashes, Decreased libido, Erectile dysfunction, Injection site reactions, Gynecomastia, Bone density loss (with prolonged use).

What does GnRH analogue (Zoladex) target?

GnRH analogue (Zoladex) targets GnRH receptor and is a GnRH agonist.

Related